Rekah Pharmaceutical Industry Balance Sheet Health
Financial Health criteria checks 3/6
Rekah Pharmaceutical Industry has a total shareholder equity of ₪164.4M and total debt of ₪104.8M, which brings its debt-to-equity ratio to 63.7%. Its total assets and total liabilities are ₪454.4M and ₪290.0M respectively. Rekah Pharmaceutical Industry's EBIT is ₪16.1M making its interest coverage ratio 2.5. It has cash and short-term investments of ₪3.7M.
Key information
63.7%
Debt to equity ratio
₪104.77m
Debt
| Interest coverage ratio | 2.5x |
| Cash | ₪3.72m |
| Equity | ₪164.37m |
| Total liabilities | ₪289.98m |
| Total assets | ₪454.36m |
Recent financial health updates
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Financial Position Analysis
Short Term Liabilities: REKA's short term assets (₪230.3M) exceed its short term liabilities (₪160.8M).
Long Term Liabilities: REKA's short term assets (₪230.3M) exceed its long term liabilities (₪129.2M).
Debt to Equity History and Analysis
Debt Level: REKA's net debt to equity ratio (61.5%) is considered high.
Reducing Debt: REKA's debt to equity ratio has increased from 57.3% to 63.7% over the past 5 years.
Debt Coverage: REKA's debt is well covered by operating cash flow (22.5%).
Interest Coverage: REKA's interest payments on its debt are not well covered by EBIT (2.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:50 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rekah Pharmaceutical Industry Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|